

**Title: Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors**

**Running Title: COVID-19 seroprevalence and hematimetry**

Author names and affiliations:

M Carmen Martín <sup>a</sup>

M Isabel González <sup>a</sup>

Nuria Holgado <sup>a</sup>

Ana I Jimenez <sup>a</sup>

Nuria Ortega <sup>a</sup>

Isabel Page <sup>a</sup>

Alba Parrado <sup>a</sup>

María Pérez <sup>a</sup>

Lydia Blanco-Peris <sup>a</sup>

<sup>a</sup> Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

**Corresponding author:** M Carmen Martín; [cmartinalo@saludcastillayleon.es](mailto:cmartinalo@saludcastillayleon.es); Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

**Sources of research support**

This work has been supported by Roche Diagnostics International Ltd., who provided free equipment and test reagents. Roche Diagnostics International Ltd. was not involved, either in study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.

## 2 **Acknowledgements**

3 LB and MCM conceived and designed the study, NH, NO; MP and AP acquired data,  
4 IP, AJ and MIGF performed analysis and interpretation of laboratory data, MCM and  
5 LB drafted the article and revised it critically for important intellectual content, all  
6 authors provided final approval of the version to be submitted.

7 The authors thank to all blood donors making this work possible by allowing  
8 research use of their samples by the Biobanco del Centro de Hemoterapia y  
9 Hemodonación de Castilla y León. They also thank the staff in charge of blood  
10 donation, and lab technicians for their efforts and Roche for its support.

## 11 **Ethical considerations**

12 This study was conducted according with national regulations, institutional  
13 policies and in the tenets of the Helsinki Declaration. This study was approved by  
14 the Valladolid Health Area Drug Research Ethics Committee, in a meeting held  
15 on June 11, 2020 with the reference number "BIO-2020-93". Included donors  
16 consented to participate in Biobank research activities. The privacy rights of  
17 human subjects were always observed.

## **Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors**

### 18 **Abstract**

19 **Background and objectives:** COVID-19 can either cause death or go unnoticed  
20 but antibodies will remain protecting us of SARS-CoV-2 reinfection for an  
21 uncertain time and to a uncertain extent. Knowledge of COVID-19  
22 epidemiological and hematological features should help make a good forecast of  
23 resources for possible future outbreaks or vaccination strategies, and would  
24 facilitate decisions in the social sphere by a more reliable estimate of the  
25 percentage of immunized individuals. Our aim was to describe seroprevalence  
26 evolution from summer 2019 to autumn 2020 in Spain and to determine its  
27 relationship with age, blood group or haematological parameters.

28 **Materials and methods:** Sera and plasma from historical donation archives were  
29 randomized and a total of 12,718 samples tested by a Chemiluminiscent analysis  
30 for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9%  
31 males, average age 46+/-13. Sex, age, blood group, blood cell counts and  
32 percentages and immunoglobulin concentrations were extracted from electronic  
33 recordings.

34 **Results:** 6.7% donors were positive by the end of 1st wave. No differences by  
35 sex, age or blood group were found regarding antibodies. Leukocyte and  
36 neutrophil counts were lower ( $p<0.001$ ) and haemoglobin was lower ( $p<0.001$ ) in  
37 positive donations than in negative ones. Sex differences were found in  
38 neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2  
39 antibodies.

40 **Conclusions:** Seroprevalence due to asymptomatic cases would be slightly  
41 lower than the overall one due to age restrictions for blood donors. Sex and age

42 would not affect COVID-19 susceptibility but its severity. Gender differences  
43 would be present in asymptomatic individuals. Further studies are needed to  
44 confirm these gender differences as they can help better understand the immune  
45 response to COVID-19, its pathogenesis and prognosis.

46

**Keywords:** COVID-19, antibodies, immunity, seroprevalence, SARS-CoV-2

#### 47 **Abbreviations**

Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM);  
polymerase chain reaction (PCR); standard deviation (SD); interquartile range  
(IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT), mean  
corpuscular volume (MCV).

#### 48 **Introduction**

49 Most SARS-CoV-2 infection cases develop an effective immune response during  
50 infection. Even these who course asymptomatic or with just mild symptoms mount  
51 humoral or cell responses. This makes it hard to calculate accurate infection or  
52 fatality rates and prevalence [1]. Immunization either due to infection or to  
53 vaccination leads to viral eradication and to specific T cell responses and  
54 antibodies against SARS-CoV-2, that usually peak 8–15 days after infection [2].  
55 Antibodies that neutralize the virus are the primary protection against COVID-19,  
56 and lymphocyte responses augment protection.

57 Antibody assays are quite different: they either detect antibodies against different  
58 viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG,  
59 IgM, IgA or their combinations. It should be noticed that every approved vaccine  
60 in Europe to date (May 2020) enhances anti-S responses, whereas an infection  
61 leads to a multi specific response to SARS-CoV2 antigens. To make it even

62 messier, many factors can influence test performance, including cross-reactivity  
63 with other coronaviruses or platform (laboratory-based vs point-of-care, lateral  
64 flow). Chemiluminescence assays have suitable performances regarding both  
65 sensibility and sensitivity while correlation to neutralizing antibodies would be  
66 around 0.7 [3].

67 Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has  
68 accumulated nearly 225.000 COVID-19 confirmed cases  
69 (<https:// analisis.datosabiertos.jcyl.es/>), with an overall case-fatality rate of 3.01 to  
70 date. Our institution, Centro de Hemoterapia de Castilla y León keeps within its  
71 Biobank plasma samples from every single donation along the last ten years, that  
72 makes up around one million samples. Any demographic data such as sex or age  
73 and laboratory parameters (blood counts, blood group, haemoglobin, etc....) is as  
74 well kept in a database (Hemasoft, eDelphyn).

75 Blood donor-based serosurveillance is a powerful and cost-effective strategy to  
76 monitor infectious diseases. There are quite a lot of infections for which routine  
77 donor screening is well known to be useful, including human immunodeficiency  
78 virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-  
79 lymphotropic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or  
80 Crimea-Congo fever. The use of blood donor samples means we're sampling  
81 mainly asymptomatic and recovered cases of COVID-19 (normal blood donation  
82 is allowed after 28 days following COVID-19 symptoms' resolution).

83 Seroprevalence surveys are then needed to monitor coronavirus pandemic, both  
84 before and after vaccination strategies [4]. Reported COVID-19 cases do not  
85 represent the full SARS-CoV-2 disease burden due to low detection rates,  
86 especially at the beginning of pandemics. Case reports are dependent on  
87 patients' seeking health care, massive local screenings or regional tracking  
88 activities. Analysis of data from seroprevalence and serosurveillance is a

89 common strategy for estimating underreporting and real disease burden. There  
90 are several features that should be taken into account, including time between  
91 infection and antibody development or antibody waning, which must be  
92 considered to understand seroprevalence surveys avoiding biases. Any  
93 seroprevalence survey should be evaluated for selection bias. Serological  
94 surveys with a random sampling design of the general population are difficult to  
95 perform in a pandemic, but a random sampling design of the general population  
96 yields a seroprevalence estimate least likely to be affected by selection bias.  
97 Blood donors are a quite representative subset of general population aged 18-65  
98 and our historical plasma collection was big enough to perform a time-layered  
99 randomization.

100 Heterogeneity of susceptibility and transmission is hard to evaluate but does exist  
101 [5]. A portion of the population is not susceptible to infection from the first  
102 pathogen contact. Some of them may have pre-existing immunity via cross-  
103 reactivity or particular host factors such as mucosal immunity or trained innate  
104 immunity protection (as it has been reported to be conferred by DTP or BCG  
105 vaccination)[6]. There is as well a proportion of seronegative individuals that will  
106 develop immunity by T cell mediated responses but without exhibiting an  
107 antibody response [7].

108 The starting hypothesis is the existence of a certain number of asymptomatic  
109 carriers of the SARS-CoV-2 virus that would develop antibodies against it [7] (and  
110 subsequently contribute to herd immunity). Those asymptomatic cases were  
111 unnoticeable before testing began and might had been circulating from an  
112 unknown moment. Early cases have been described in France [8], arising the  
113 question of whether the pathogen could have been circulating even before the  
114 official recording of the first cases.-The main aim of this study was to determine  
115 what percentage of the population has had contact with SARS-CoV-2 at different

116 times and has therefore developed antibodies against it. A secondary goal was to  
117 describe haematological features of seropositive donors and establish whether  
118 sex, age, blood group or haematological abnormalities were related COVID-19  
119 exposure.

120 Knowledge of COVID-19 epidemiological and hematological features should help  
121 make a good forecast of resources for possible future outbreaks or vaccination  
122 strategies, and would facilitate decisions in the social sphere by a more reliable  
123 estimate of the percentage of immunized individuals.

## 124 **MATERIAL and METHODS**

### 125 *Aim, design and setting of the study*

126 The aim of this study was to analytically obtain, a reliable knowledge of  
127 asymptomatic COVID-19 cases and their immunological and haematological  
128 characteristics, seroprevalence, rate of positive donations and its temporal  
129 evolution along the first wave in Spain. So, a retrospective observational analysis  
130 was performed.

### 131 *Participants*

132 The Biobank is included in the National Registry of Biobanks (RD17 / 16/2011)  
133 with the number B.0000264. The institution holds an ISO 9001: 2015 certification  
134 endorsing our granting of safety and traceability of any human biological sample  
135 we distribute, always behaving Spanish and European rules on human samples  
136 and data protection management.

137 The study population comprised randomised plasma-EDTA and serum frozen  
138 samples from blood, plasma (excluding convalescent) and platelet donations  
139 from July 2019 to October 2020. Donations collected since 19/07/2019 (week -  
140 24) to 19/10/2020 (week 43) were randomized to select a minimum of 150

141 donations per week. A total of 12,718 samples of 11,444 donors over 18 years  
142 old were included.

### 143 *Laboratory data and analyses*

144 All haematological and demographic data were extracted from electronic  
145 database eDelphyn (Hemasoft). Variables analyzed included age, sex, blood  
146 group, and laboratory data.

147 Major laboratory markers were extracted from our donation database. Routine  
148 blood examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet,  
149 monocyte, eosinophil and basophil counts (cells\*10<sup>3</sup>/μL) and their percentages.  
150 Serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb),  
151 haematocrit (HCT) and corpuscular mean volume were analysed as well.

152 An automated chemiluminiscence double-antigen sandwich immunoassay for the  
153 in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human  
154 serum and plasma was performed. The target antigen of this immunoassay is a  
155 recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche,  
156 Basel, Switzerland) detects antibodies correlating with virus-neutralizing ones  
157 and is therefore useful to help characterize the immune reaction to SARS-CoV-2  
158 [9, 10]. Immunoassay was validated by our serology lab by testing of 6 pairs of  
159 samples (plasma EDTA and serum) from diagnosed PCR-positive, symptomatic  
160 cases infected by mid-April, that were previously reported positive by the Spanish  
161 National Microbiology Centre, and checked to be as well positive for IgG  
162 (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) and IgA (ELISA,  
163 S protein, Euroimmun, Lübeck, Germany) antiSARS-CoV-2. Another set of ten  
164 prepandemic samples, therefore supposed to be negative, were equally  
165 analyzed. A 100% concordance was yielded by these validation assays. The cut-  
166 off was that recommended by manufacturer (OD>1 to report reactivity).  
167 Researchers performing anti SARS-CoV-2 analyses were blind to the condition of



168 COVID-19 convalescence and to any other characteristic of the donors or to the  
169 donation dates.

### 170 *Statistical analysis*

171 Demographic and clinical characteristics of patients are expressed as their mean  
172 and standard deviation (SD) for continuous variables and frequency distributions  
173 are reported for categorical variables. Age was analysed both as continuous and  
174 categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-  
175 60, 60-75 years old.


176 Kolmogorov-Smirnov test was performed on each continuous variable to contrast  
177 normality. Only IgG and IgM serum levels followed normal distributions, therefore  
178 non-parametric Mann-Whitney U test was performed to compare laboratory  
179 values. To contrast the hypothesis of independence within categorical variables,  
180 Pearson's Chi-square and Fisher's exact test were carried out. All tests were  
181 calculated with a confidence level of 0.05.

### 182 **Results**

183 A total of 12,718 randomized donations (either whole blood, plasmapheresis or  
184 platelet apheresis) were tested for total anti SARS-CoV2 antibodies. Donors  
185 made up 11,444, 60.91% males, aged 18-75, average 46+/-13, 45.8% A, 40.3%  
186 O, 10.56% B, 3.31% AB.

187 Seropositivity rate grew up from week 11 to week 25, reaching a 11.1% peak,  
188 with just subtle descents until week 43 when 2<sup>nd</sup> wave arose in our country.  
189 Plateau was reached by the last week of May 2020, 11 weeks after close  
190 lockdown in Spain (that begun in March, 15<sup>th</sup>) and 17 weeks after 31/01, the date  
191 of the first declared case in our country. 660 out of 9,886 single donors were  
192 positive within weeks 11 to 43, that makes a seroprevalence of 6.73% at the end  
193 of the first wave.

194 Three 2019 donations were reactive (from July, September and October) but  
 195 none of them were positive when testing separately IgG, IgA or IgM. Their ODs  
 196 were 1.05, 1.08 and 5.46 respectively. 1,142 donations from year 2019 were  
 197 analyzed.



198  
 199 Figure 1. COVID-19 seropositive donation rate 2020 evolution by weeks. Temporal  
 200 series' model (mobile median t=6; exponential smoothing model R[2]=0.991;p<0.001)  
 201 No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of  
 202 donors were found (Table 1).

	Negative		Positive	
	n	%	n	%
Female	4531	38.1%	164	40.3%
Male	7375	61.9%	243	59.7%
<30	3551	29.8%	104	25.6%
30 to 45	5036	42.3%	180	44.2%
45 to 60	1151	9.7%	42	10.3%
60 to 75	2168	18.2%	81	19.9%
A	5411	45.5%	198	48.6%
AB	423	3.6%	16	3.9%
B	919	7.7%	22	5.4%
O	5151	43.3%	171	42.0%

203 Table 1. Sex, age range and blood group of positive/negative anti SARS-COV2 donations  
 204 analysed

205 Immunoglobulin levels didn't show any differences as comparing positive and  
206 negative donations. Haemoglobin (14.9 vs 14.7 g/dL;  $p < 0.001$ ) and haematocrit  
207 (45.2% vs 44.4%;  $p < 0.001$ ) were both significantly lower in positive donations .  
208 Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells\* $10^3/\mu\text{L}$ ;  
209  $p = 0.026$ ) (Table 2). A trend was found of lower number of neutrophils (4.3 vs. 4.2  
210 cells\* $10^3/\mu\text{L}$ ;  $p = 0.117$ ), lower count of monocytes (0.46 vs. 0.45 cells\* $10^3/\mu\text{L}$ ;  
211  $p = 0.117$ ) and higher percent of basophils (0.49% vs 0.51%;  $p = 0.131$ ).

212 As layering data by sex (Table 3), the fact arose that haematocrit (46.8% vs  
213 45.9%;  $p < 0.001$ ) and haemoglobin (15.5 vs 15.3 g/dL;  $p < 0.001$ ) were significantly  
214 lower just in males and that positive females had significantly less WBC (7.67 vs  
215 7.25 cells\* $10^3/\mu\text{L}$ ;  $p = 0.027$ ) and neutrophil numbers (4.53 vs 4.27  
216 cells\* $10^3/\mu\text{L}$ ;  $p = 0.014$ ).

217 Some trends were found as well related to sex. Regarding positive women  
218 neutrophil percent would be lower (59.4% vs 58.10%  $p = 0.065$ ), with a higher  
219 lymphocyte percent (31.7% vs 33.10%;  $p = 0.074$ ) a lower platelet count (261 vs  
220 255 cells\* $10^3/\mu\text{L}$ ;  $p = 0.152$ ), monocyte count (0.46 vs 0.44 cells\* $10^3/\mu\text{L}$ ;  $p = 0.132$ )  
221 and basophil percent (0.5% vs 0.4%;  $p = 0.060$ ). Anaemia was more frequent in  
222 positive male donors as (6.1% vs 9.6%;  $p = 0.031$ ), A trend of. No other significant  
223 differences were found either in males, females or overall. Figure 2 summarize  
224 these findings.

	Overall	Male	Female
Hb	↓	↓	-
Hematocrite	↓	↓	-
Leukocyte count	↓	-	↓
Platelet count	-	-	↓
Neutrophil count	↓	-	↓
Neutrophil %	-	-	↑
Lymphocyte count	-	-	↓
Lymphocyte %	-	-	↓
Monocyte count	↓	-	↓
Basophil %	↑	-	↓

225

226 Figure 2. Haematological features in SARS-CoV-2 positive donations. Intense-  
 227 coloured arrows represent significant differences. Light-coloured arrows  
 228 represent statistical trends.

## 229 Discussion

230 A slightly lower seroprevalence than that found in general population was found  
 231 among blood donors without COVID-19 antecedents. The 6.73% seroprevalence  
 232 we found is a little lower than that reported in the seroprevalence study ENE-  
 233 COVID-19 promoted by the *Instituto Nacional the Epidemiología* [11], where it is  
 234 reported that a 7.2% of the participants in our region would have anti SARS-  
 235 CoV2 IgG antibodies by the end of June 2020. Almost one quarter people in our  
 236 region (25.51% according to National Institute of Statistics, INE 2020 data) is  
 237 older than 65 and elderly are necessarily underrepresented in this study as it  
 238 comprises blood donors. That happens as well with population aged less than 18  
 239 (under 4.5% in our region). One limitation of this study is that of age, restricted to  
 240 18-75 years old, but it would make just a little difference of 0.5% in  
 241 seroprevalence estimation. Immunization rate would be a bit higher regarding the  
 242 fact that some individuals do not exhibit antibodies but still mount an efficient  
 243 specific T-cell response [2]

244 Perhaps the main strength of our study is the large number of samples we  
245 randomized and tested along almost one year. The first recorded COVID-19 case  
246 in Spain was reported on 31/01/2020, but 3 positive donations were found as  
247 testing samples collected along 2019. That could be meaningful in two opposite  
248 ways: one possible explanation would be cross reactivity to seasonal cold  
249 coronaviruses and the other would be that SARS-CoV-2 might have been  
250 circulating at least since 2019 summer.

251 It is now known that up to 28% people would have protection against SARS-CoV-  
252 2 due to cross reaction to other coronaviruses [2]. It has been checked that long-  
253 term cross-reactive both T-cell and antibodies can be a correlate of protections  
254 against COVID-19 [12]. Asymptomatic or mild cases couldn't be diagnosed or  
255 reported until the first tests were developed in the first term of 2020. There are  
256 other reports about SARS-CoV-2 circulating in Europe along 2019. Italy's Ministry  
257 of Health reported high levels of unusual strains of flu and pneumonia  
258 concentrated in the area around Milan and appearing in 17 of Italy's 20 regions  
259 [13]. Our three 2019 positive donors would be even earlier cases, but the  
260 simplest explanation would be that of cross reaction. In fact, we cannot 100%  
261 ascertain whether some of the positives along the period of study might be cross  
262 reactions as well or both reactive due to SARS-CoV-2 infection together with  
263 previous coronavirus immunity.

264 Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have an  
265 influence on the probability to develop an asymptomatic COVID-19 infection in  
266 our cohort. Several smaller seroprevalence reports from European countries  
267 support this feature [16-20]. It may be therefore ascertained that age and sex do  
268 not have a role in SARSCoV-2 infection susceptibility, but only in their  
269 progression to severe forms.

270 Blood group has been reported elsewhere [7,21-23] to confere susceptibility or  
271 determine severity of SARS-CoV2 infection. Most studies do not separate  
272 susceptibility and severity. It should be noticed that there are no large studies  
273 characterizing asymptomatic cases in literature, perhaps this is one of the reports  
274 comprising more asymptomatic individuals. Relationship of ABO system with  
275 susceptibility is not supported by our data. We excluded convalescent plasma  
276 donors, opposite to other studies, that focused into these asymptomatic positive  
277 donors [22]. Perhaps blood group might be related only to symptomatic cases  
278 and would be therefore related to severity but not related to asymptomatic SARS-  
279 CoV-2 infection. Another surface antigens such as HLA or KIR might be as well  
280 involved and should be studied.

281 Several blood count anomalies have been reported to be associated to SARS-  
282 CoV2 infection, notably lymphopenia and neutrophilia are related to severest  
283 forms [24]. Our data conversely reveal that asymptomatic positive women had a  
284 significant lower count of WBC and neutrophils as compared to negative ones.  
285 Similar low counts of WBC and neutrophils have been reported in young (<19)  
286 cohorts, comprising mainly mild and asymptomatic cases [25]. Perhaps this  
287 feature might be therefore a correlate of mildness. Elevation of monocytes have  
288 been elsewhere reported in short series of mild cases [26]. Our observation in will  
289 be in the same line of those findings but a gender bias cannot be discarded so far  
290 seropositive women would go in the opposite direction.

291 Several reports about haemolytic anaemia secondary to SARSCoV-2 have been  
292 published [27-30]. We cannot discard the possibility of a mild silent haemolytic  
293 anaemia in asymptomatic cases. Again, little analysis of asymptomatic cases is  
294 available by the moment.

295 We can conclude that seroprevalence estimations through blood donation  
296 analysis resemble data obtained from population-based surveys. Sex and age

297 would not affect COVID-19 susceptibility but its severity. Gender differences are  
298 present even in asymptomatic individuals: females are known to develop milder  
299 COVID-19, this fact might be related to a lower WBC count whereas positive  
300 males although asymptomatic, present anaemia more frequently than negative  
301 ones. Further studies in large cohorts are needed to confirm these gender  
302 differences and to characterize asymptomatic COVID-19 cases as they can help  
303 better understand immune response to COVID-19, its pathogenesis and  
304 prognosis.

### 305 **Availability of data and materials**

306 The data that support the findings of this study are not openly available due to reasons  
307 of sensitivity and are available from the corresponding author upon reasonable request  
308 and after mandatory approval of proposals by the Valladolid Este Ethical Committee

309

310

### 311 **References**

- 312 1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory  
313 Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood  
314 Donor Populations. *Clin Infect Dis.* 2020;72(2):254-256
- 315 2. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A,  
316 et al. Robust T Cell Immunity in Convalescent Individuals with  
317 Asymptomatic or Mild COVID-19. *Cell.* 2020 Oct 1;183(1):158-168.e14. doi:  
318 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID:  
319 PMC7427556.
- 320 3. Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys  
321 HB, van der Schoot E. Evaluation of SARS-CoV-2 antibody titers and  
322 potency for convalescent plasma donation: a brief commentary. *Vox Sang.*  
323 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23.  
324 PMID: 33368373.
- 325 4. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections,  
326 Symptomatic Infections, Hospitalizations, and Deaths Using  
327 Seroprevalence Surveys. *JAMA Netw Open.* 2021;4(1):e2033706

- 328 5. Friston K, Costello A, Pillay D. 'Dark matter', second waves and  
329 epidemiological modelling. *BMJ Glob Health*. 2020;5(12):e003978
- 330 6. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care  
331 providers and the protection against COVID-19. *J Clin Invest*.  
332 2021;131(2):e145545
- 333 7. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibia J, Candon S,  
334 Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with  
335 Cellular Immune Response without Seroconversion, France. *Emerg Infect*  
336 *Dis*. 2021;27(1):113–21
- 337 8. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X.  
338 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O  
339 French blood donors. *Antiviral Res*. 2020;181:104880
- 340 9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical  
341 evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin*  
342 *Virol*. 2020;129:104480
- 343 10. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2  
344 serological assays in a high-prevalence setting [published online ahead of  
345 print, 2021 Feb 3]. *Eur J Clin Microbiol Infect Dis*. 2021;1-9
- 346 11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk  
347 for SARS-CoV-2 in community dwelling population of Spain: nationwide  
348 seroepidemiological study. *BMJ*. 2020;371:m4509
- 349 12. Poonia B, Kottlilil S. Immune Correlates of COVID-19 Control. *Front*  
350 *Immunol*. 2020;11:569611
- 351 13. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in  
352 emergency departments as a COVID-19 surveillance system: a time series  
353 study. *BMJ Open*. 2021;11(2):e044388.
- 354 14. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-  
355 reactive protein, and lymphocytes as key clues from a multicentre retrospective  
356 study. *Immun Ageing*. 2020;17:22
- 357 15. Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The  
358 age again in the eye of the COVID-19 storm: evidence-based decision making.  
359 *Immun Ageing*. 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w.  
360 PMID: 34016150; PMCID: PMC8134808.
- 361
- 362 16. Dickson E, Palmateer NE, Murray J, et al. Enhanced surveillance of COVID-  
363 19 in Scotland: population-based seroprevalence surveillance for SARS-  
364 CoV-2 during the first wave of the epidemic. *Public Health*. 2021;190:132-  
365 134
- 366 17. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in  
367 Brazil: results from two successive nationwide serological household  
368 surveys. *Lancet Glob Health*. 2020;8(11):e1390-e1398.



- 369 18. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey  
370 of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro*  
371 *Surveill.* 2020;25(31):2001369
- 372 19. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community  
373 Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April  
374 28-May 3, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(29):965-970
- 375 20. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-  
376 CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a  
377 population-based study. *Lancet.* 2020;396(10247):313-319
- 378 21. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood  
379 Types and COVID-19: Spurious, Anecdotal, or Truly Important  
380 Relationships? A Reasoned Review of Available Data. *Viruses.*  
381 2021;13(2):160
- 382 22. Muñoz-Díaz E, Llopis J, Parra R, et al. Relationship between the ABO blood  
383 group and COVID-19 susceptibility, severity and mortality in two cohorts  
384 of patients. *Blood Transfus.* 2021;19(1):54-63
- 385 23. Zalba Marcos S, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA.  
386 Infection and thrombosis associated with COVID-19: Possible role of the ABO  
387 blood group. *Infección y trombosis asociada a la COVID-19: posible papel del*  
388 *grupo sanguíneo ABO. Med Clin (Barc).* 2020;155(8):340-343.  
389 doi:10.1016/j.medcli.2020.06.020
- 390 24. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From  
391 cytopenia to coagulopathy. *Eur J Haematol.* 2020;105(5):540-546
- 392 25. Toba N, Gupta S, Ali AY, ElSaban M, Khamis AH, Ho SB, Popatia R. COVID-19  
393 under 19: A meta-analysis. *Pediatr Pulmonol.* 2021 Jun;56(6):1332-1341. doi:  
394 10.1002/ppul.25312. Epub 2021 Feb 25. PMID: 33631060; PMCID: PMC8013606
- 395 26. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical  
396 and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection.  
397 *Cytometry A.* 2020 Sep;97(9):887-890. doi: 10.1002/cyto.a.24188. Epub 2020  
398 Aug 14. PMID: 32654350; PMCID: PMC7404377
- 399 27. Gruden G, Beggiato E, Camerino E, Capriotti S, Canepa S, Scandella M,  
400 Avolio M, Pittalunga F, Barutta F, Durazzo M. Treatment with eltrombopag  
401 of severe immune thrombocytopenia and hemolytic anemia associated  
402 with COVID-19 pneumonia: a case report. *Ther Adv Hematol.* 2021 Apr  
403 27;12:20406207211011353. doi: 10.1177/20406207211011353. PMID:  
404 33995989; PMCID: PMC8082984.
- 405 28. Liput JR, Jordan K, Patadia R, Kander E. Warm Autoimmune Hemolytic  
406 Anemia Associated With Asymptomatic SARS-CoV-2 Infection. *Cureus.*  
407 2021 Mar 25;13(3):e14101. doi: 10.7759/cureus.14101. PMID: 33927918;  
408 PMCID: PMC8075761.
- 409 29. Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ,  
410 Iyadurai R. Evans syndrome and immune thrombocytopenia in two  
411 patients with COVID-19. *J Med Virol.* 2021 May;93(5):2642-2644. doi:

412 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID:  
413 PMC8013600.

414 30. Mausoleo A, Henriquez S, Goujard C, Roque-Afonso AM, Noel N,  
415 Lambotte O. Severe IgA-mediated autoimmune hemolytic anemia  
416 triggered by SARS-CoV-2 infection. *Leuk Lymphoma*. 2021 Feb 22;1-5. doi:  
417 10.1080/10428194.2021.1888378. Epub ahead of print. PMID: 33618609.

418 31. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving  
419 Reactive Oxygen Species and Myeloperoxidase Explains Clinical  
420 Deterioration and Fatality in COVID-19. *Int J Biol Sci*. 2021 Jan 1;17(1):62-  
421 72

422 32. Dattilo M. The role of host defences in Covid 19 and treatments  
423 thereof. *Mol Med*. 2020;26(1):90

424

425

426 **Tables**

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	<b>45.8</b>	12.8	34.2-54.2
	Positive	407	44.2	<b>46.5</b>	13.0	32.8-54.8
IgA	Negative	194	236.9	<b>223.5</b>	101.3	163-292
	Positive	5	224.4	<b>274.0</b>	92.3	134-282
IgG	Negative	194	1065.4	<b>1037.5</b>	217.4	910-1185
	Positive	5	1123.8	<b>1095.0</b>	249.9	924-1229
IgM	Negative	194	113.3	<b>100.5</b>	64.8	69-138
	Positive	5	103.0	<b>89.0</b>	41.7	78-97
WBC (p=0.026)	Negative	9759	7.4	<b>7.2</b>	1.8	6.13-8.49
	Positive	346	7.2	<b>7.1</b>	1.6	6.11-8.12
Hb (p<0.001)	Negative	11218	14.9	<b>14.9</b>	1.3	14-15.8
	Positive	386	14.7	<b>14.7</b>	1.2	13.8-15.4
Hematocrite (p<0.001)	Negative	11218	45.1	<b>45.2</b>	3.5	42.7-47.6
	Positive	386	44.5	<b>44.4</b>	3.5	42.3-46.6
Platelets	Negative	11217	247.9	<b>243.0</b>	54.3	211-280
	Positive	386	247.3	<b>242.5</b>	55.7	206-276
Neutrophil count (p=0.117)	Negative	11217	4.4	<b>4.3</b>	1.4	3.44-5.19
	Positive	386	4.3	<b>4.2</b>	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	<b>58.9</b>	7.5	53.8-63.9
	Positive	386	58.5	<b>58.7</b>	7.1	54.3-63.4
Lymphocyte count	Negative	11216	2.3	<b>2.3</b>	0.7	1.86-2.72
	Positive	386	2.3	<b>2.2</b>	0.6	1.89-2.64
Lymphocyte %	Negative	11216	31.7	<b>31.5</b>	6.9	27-36.2
	Positive	386	32.1	<b>32.4</b>	6.6	27.3-36.1
Monocyte count (p=0.131)	Negative	11216	0.5	<b>0.46</b>	0.1	0.38-0.56
	Positive	386	0.5	<b>0.46</b>	0.1	0.37-0.54
Monocyte %	Negative	11216	6.5	<b>6.4</b>	1.5	5.5-7.4
	Positive	386	6.5	<b>6.4</b>	1.4	5.5-7.3
Eosinophil count	Negative	11217	0.2	<b>0.2</b>	0.1	0.09-0.23
	Positive	386	0.2	<b>0.1</b>	0.1	0.09-0.22
Eosinophil %	Negative	11217	2.5	<b>2.1</b>	1.8	1.3-3.2
	Positive	386	2.4	<b>2.0</b>	1.7	1.3-3.1
Basophil count	Negative	11217	0.0	<b>0.0</b>	0.0	0.02-0.04
	Positive	386	0.0	<b>0.0</b>	0.0	0.02-0.04
Basophil %	Negative	11217	0.5	<b>0.5</b>	0.2	0.3-0.6
	Positive	386	0.5	<b>0.5</b>	0.3	0.4-0.6

427 Table 2. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), hemogram  
 428 counts (cells\*10<sup>3</sup>/μL) and percentages of reactive and non-reactive donations

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	<b>43.50</b>	13.3	30.3-53.3
		Positive	164	42.1	<b>45.39</b>	13.6	28.6-53.1
	Male	Negative	7375	45.2	<b>46.81</b>	12.2	36.7-54.8
		Positive	243	45.7	<b>46.98</b>	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	<b>200.00</b>	97.0	157-250
		Positive	3	235.3	<b>274.00</b>	105.5	116-316
	Male	Negative	140	245.6	<b>233.50</b>	101.9	176.5-302.5
		Positive	2	208.0	<b>208.00</b>	104.7	134-282
IgG	Female	Negative	54	1076.4	<b>1062.50</b>	191.3	964-1186
		Positive	3	1082.7	<b>1095.00</b>	152.9	924-1229
	Male	Negative	140	1061.2	<b>1029.00</b>	227.2	903-1181.5
		Positive	2	1185.5	<b>1185.50</b>	436.3	877-1494
IgM	Female	Negative	54	143.1	<b>129.50</b>	64.6	94-169
		Positive	3	114.3	<b>89.00</b>	53.7	78-176
	Male	Negative	140	101.8	<b>90.00</b>	61.3	64.5-121
		Positive	2	86.0	<b>86.00</b>	15.6	75-97
MCV	Female	Negative	3618	91.2	<b>91.50</b>	4.8	88.4-94.4
		Positive	142	91.2	<b>91.40</b>	4.1	88.9-93.5
	Male	Negative	6141	90.9	<b>91.00</b>	4.6	88.1-93.8
		Positive	204	90.6	<b>91.00</b>	4.8	88-94.1
WBC	Female*	Negative	3618	7.8	<b>7.69</b>	1.9	6.49-9
		Positive	142	7.4	<b>7.21</b>	1.5	6.27-8.26
	Male	Negative	6949	7.2	<b>7.02</b>	1.8	5.99-8.2
		Positive	229	7.1	<b>6.98</b>	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	<b>13.80</b>	0.9	13.2-14.4
		Positive	157	13.7	<b>13.80</b>	0.9	13.2-14.3
	Male*	Negative	6949	15.5	<b>15.50</b>	1.0	14.9-16.2
		Positive	229	15.3	<b>15.30</b>	1.0	14.7-15.8
HCT	Female	Negative	4269	42.4	<b>42.30</b>	2.7	40.6-44
		Positive	157	42.1	<b>42.00</b>	2.5	40.5-43.6
	Male*	Negative	6949	46.8	<b>46.80</b>	2.8	45-48.6
		Positive	229	46.2	<b>45.90</b>	3.0	44.3-47.7
PLT	Female	Negative	4268	265.9	<b>261.00</b>	56.6	228-300
		(t) Positive	157	261.0	<b>255.00</b>	60.5	219-296
	Male	Negative	6949	236.8	<b>233.00</b>	49.6	204-266
		Positive	229	237.9	<b>234.00</b>	50.2	203-266
Neutrophil count	Female*	Negative	4268	4.7	<b>4.53</b>	1.4	3.65-5.47
		Positive	157	4.4	<b>4.27</b>	1.2	3.56-5.08
	Male	Negative	6949	4.3	<b>4.10</b>	1.4	3.34-4.95
		Positive	229	4.2	<b>4.10</b>	1.2	3.24-4.97
Neutrophil %	Female	Negative	4268	59.2	<b>59.40</b>	7.4	54.2-64.3
		Positive	157	58.1	<b>58.10</b>	7.2	54-62.9
	Male	Negative	6949	58.6	<b>58.70</b>	7.5	53.6-63.6
		Positive	229	58.8	<b>58.70</b>	7.0	54.6-63.5

Lymphocyte count	Female*	Negative	4267	2.5	<b>2.39</b>	0.7	1.97-2.88
		Positive	157	2.4	<b>2.35</b>	0.6	2.02-2.81
	Male	Negative	6949	2.2	<b>2.18</b>	0.6	1.8-2.62
		Positive	229	2.2	<b>2.17</b>	0.6	1.8-2.51
Lymphocyte %	Female	Negative	4267	32.0	<b>31.70</b>	6.9	27.4-36.5
		(t) Positive	157	33.0	<b>33.10</b>	7.0	28.4-37
	Male	Negative	6949	31.5	<b>31.30</b>	6.9	26.8-36.1
		Positive	229	31.4	<b>31.70</b>	6.3	26.7-35.6
Monocyte count	Female	Negative	4267	0.5	<b>0.46</b>	0.1	0.37-0.55
		(t) Positive	157	0.5	<b>0.44</b>	0.1	0.36-0.52
	Male	Negative	6949	0.5	<b>0.46</b>	0.1	0.38-0.56
		Positive	229	0.5	<b>0.47</b>	0.1	0.38-0.55
Monocyte %	Female	Negative	4267	6.1	<b>6.00</b>	1.4	5.1-6.9
		Positive	157	6.1	<b>6.00</b>	1.4	5.2-6.9
	Male	Negative	6949	6.7	<b>6.60</b>	1.5	5.7-7.6
		Positive	229	6.7	<b>6.70</b>	1.4	5.8-7.6
Eosinophil count	Female	Negative	4268	0.2	<b>0.14</b>	0.1	0.09-0.21
		Positive	157	0.2	<b>0.13</b>	0.1	0.09-0.19
	Male	Negative	6949	0.2	<b>0.16</b>	0.1	0.1-0.24
		Positive	229	0.2	<b>0.15</b>	0.1	0.09-0.23
Eosinophil %	Female	Negative	4268	2.2	<b>1.80</b>	1.6	1.2-2.8
		Positive	157	2.3	<b>1.80</b>	1.7	1.1-2.8
	Male	Negative	6949	2.7	<b>2.20</b>	1.8	1.4-3.4
		Positive	229	2.5	<b>2.10</b>	1.7	1.4-3.2
Basophil count	Female	Negative	4268	0.0	<b>0.03</b>	0.0	0.02-0.05
		Positive	157	0.0	<b>0.04</b>	0.0	0.02-0.05
	Male	Negative	6949	0.0	<b>0.03</b>	0.0	0.02-0.04
		Positive	229	0.0	<b>0.03</b>	0.0	0.02-0.04
Basophil %	Female	Negative	4268	0.5	<b>0.40</b>	0.2	0.3-0.6
		(t) Positive	157	0.5	<b>0.50</b>	0.3	0.3-0.6
	Male	Negative	6949	0.5	<b>0.50</b>	0.2	0.3-0.6
		Positive	229	0.5	<b>0.50</b>	0.2	0.4-0.6

430 \*p<0.01

431 (t) p<0.2

432 Table 3. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), MCV,  
 433 hemogram counts (cells\*10<sup>3</sup>/μL) and percents, of reactive and non-reactive donations  
 434 by sex.

435

436